Patrick Trucchio
Stock Analyst at HC Wainwright & Co.
(2.74)
# 1,959
Out of 4,711 analysts
297
Total ratings
29.53%
Success rate
0.84%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Patrick Trucchio
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARWR Arrowhead Pharmaceuticals | Reiterates: Buy | $80 | $19.45 | +311.31% | 20 | Dec 20, 2024 | |
| SGMO Sangamo Therapeutics | Reiterates: Buy | $10 | $2.47 | +304.86% | 22 | Dec 20, 2024 | |
| HRMY Harmony Biosciences Holdings | Initiates: Buy | $75 | $34.28 | +118.79% | 1 | Dec 17, 2024 | |
| QURE uniQure | Reiterates: Buy | $25 | $16.98 | +47.23% | 11 | Dec 10, 2024 | |
| BEAM Beam Therapeutics | Reiterates: Buy | $80 | $29.01 | +175.77% | 4 | Dec 9, 2024 | |
| SLN Silence Therapeutics | Reiterates: Buy | $75 | $6.88 | +990.12% | 20 | Dec 9, 2024 | |
| VIR Vir Biotechnology | Reiterates: Buy | $110 | $7.34 | +1,398.64% | 20 | Nov 20, 2024 | |
| IVVD Invivyd | Maintains: Buy | $15 → $10 | $0.44 | +2,152.76% | 14 | Nov 20, 2024 | |
| GHRS GH Research | Reiterates: Buy | $40 | $6.85 | +483.94% | 11 | Nov 20, 2024 | |
| CYBN Cybin | Reiterates: Buy | $190 | $9.61 | +1,877.11% | 15 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $400 | $245.44 | +62.97% | 22 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $10 | $1.19 | +740.34% | 14 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $0.83 | +501.68% | 15 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $8.25 | +45.45% | 12 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $5.75 | +421.74% | 6 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $0.84 | +1,090.48% | 14 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $55 | $7.16 | +668.16% | 16 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $60 | $3.97 | +1,411.34% | 12 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $100 | $28.33 | +253.05% | 16 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $25 | $1.80 | +1,288.89% | 14 | Oct 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $60 | $4.72 | +1,171.19% | 13 | Aug 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $170 → $68 | $11.41 | +495.97% | 2 | Sep 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $230 → $20 | $1.20 | +1,566.67% | 2 | Dec 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $260 → $340 | $242.49 | +40.21% | 1 | Aug 18, 2021 |
Arrowhead Pharmaceuticals
Dec 20, 2024
Reiterates: Buy
Price Target: $80
Current: $19.45
Upside: +311.31%
Sangamo Therapeutics
Dec 20, 2024
Reiterates: Buy
Price Target: $10
Current: $2.47
Upside: +304.86%
Harmony Biosciences Holdings
Dec 17, 2024
Initiates: Buy
Price Target: $75
Current: $34.28
Upside: +118.79%
uniQure
Dec 10, 2024
Reiterates: Buy
Price Target: $25
Current: $16.98
Upside: +47.23%
Beam Therapeutics
Dec 9, 2024
Reiterates: Buy
Price Target: $80
Current: $29.01
Upside: +175.77%
Silence Therapeutics
Dec 9, 2024
Reiterates: Buy
Price Target: $75
Current: $6.88
Upside: +990.12%
Vir Biotechnology
Nov 20, 2024
Reiterates: Buy
Price Target: $110
Current: $7.34
Upside: +1,398.64%
Invivyd
Nov 20, 2024
Maintains: Buy
Price Target: $15 → $10
Current: $0.44
Upside: +2,152.76%
GH Research
Nov 20, 2024
Reiterates: Buy
Price Target: $40
Current: $6.85
Upside: +483.94%
Cybin
Nov 19, 2024
Reiterates: Buy
Price Target: $190
Current: $9.61
Upside: +1,877.11%
Nov 18, 2024
Reiterates: Buy
Price Target: $400
Current: $245.44
Upside: +62.97%
Nov 18, 2024
Maintains: Buy
Price Target: $15 → $10
Current: $1.19
Upside: +740.34%
Nov 14, 2024
Reiterates: Buy
Price Target: $5
Current: $0.83
Upside: +501.68%
Nov 14, 2024
Reiterates: Buy
Price Target: $12
Current: $8.25
Upside: +45.45%
Nov 14, 2024
Reiterates: Buy
Price Target: $30
Current: $5.75
Upside: +421.74%
Nov 11, 2024
Reiterates: Buy
Price Target: $10
Current: $0.84
Upside: +1,090.48%
Nov 11, 2024
Reiterates: Buy
Price Target: $55
Current: $7.16
Upside: +668.16%
Nov 1, 2024
Maintains: Buy
Price Target: $120 → $60
Current: $3.97
Upside: +1,411.34%
Oct 24, 2024
Reiterates: Buy
Price Target: $100
Current: $28.33
Upside: +253.05%
Oct 14, 2024
Reiterates: Buy
Price Target: $25
Current: $1.80
Upside: +1,288.89%
Aug 22, 2024
Reiterates: Buy
Price Target: $60
Current: $4.72
Upside: +1,171.19%
Sep 23, 2022
Maintains: Buy
Price Target: $170 → $68
Current: $11.41
Upside: +495.97%
Dec 28, 2021
Maintains: Buy
Price Target: $230 → $20
Current: $1.20
Upside: +1,566.67%
Aug 18, 2021
Maintains: Outperform
Price Target: $260 → $340
Current: $242.49
Upside: +40.21%